A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research...

por Steinbild, S, Mross, K, Frost, A, Morant, R, Gillessen, S, Dittrich, C, Strumberg, D, Hochhaus, A, Hanauske, A-R, Edler, L, Burkholder, I, Scheulen, M
Publicado 2007

Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial

por Morant, R, Bernhard, J, Dietrich, D, Gillessen, S, Bonomo, M, Borner, M, Bauer, J, Cerny, T, Rochlitz, C, Wernli, M, Gschwend, A, Hanselmann, S, Hering, F, Schmid, H-P
Publicado 2004

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

por Van Cutsem, E, Dirix, L, Van Laethem, J-L, Van Belle, S, Borner, M, Gonzalez Baron, M, Roth, A, Morant, R, Joosens, E, Gruia, G, Sibaud, D, Bleiberg, H
Publicado 2005

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer

por Thatcher, N, Campos, E S De, Bell, D R, Steward, W P, Varghese, G, Morant, R, Vansteenkiste, J F, Rosso, R, Ewers, S-B, Sundal, E, Schatzmann, E, Stocker, H
Publicado 1999